Competing interests

DB: declares no conflicts of interest. PJH: Research funding (to institution): BeOne, AstraZeneca. Consultancy and Honorarium (compensation to the institution): AbbVie. LER: Consulting: AbbVie, Ascentage, AstraZeneca, Beigene, Janssen, Loxo Oncology, Pharmacyclics; Data safety monitoring committee (DSMC) member: Ascentage; CME speaker: DAVA, Curio, Medscape, and PeerView; Minority ownership interest: Abbott Laboratories; Travel support: LOXO oncology, Research funding (to institution): Adaptive Biotechnologies, AstraZeneca, Genentech, AbbVie, Pfizer, Loxo Oncology, Aptose Biosciences, Dren Bio, and Qilu Puget Sound Biotherapeutics. NEK: Advisory Board for: AbbVie, Astra Zeneca, Beigene, Janssen, Pharmacyclics, DSMC (Data Safety Monitoring Committee) for: AstraZeneca, BMS-Celgene, Dren Bio, Research funding: AbbVie, Acerta Pharma, Astra Zeneca, Pharmacyclics/Jannsen, Merck. TH: Research funding (to institution): BeiGene, BMS; Advisory Board: BeiGene. SAP: Research funding: Janssen, AstraZeneca, Merck, and Genentech for clinical studies in which Sameer A. Parikh is a principal investigator. Honoraria: Pharmacyclics, Merck, AstraZeneca, Janssen, BeiGene, Genentech, SoBi, MingSight Pharmaceuticals, Novalgen Limited, Kite Pharma, and AbbVie for Sameer A. Parikh’s participation in consulting activities/advisory board meetings. YW: Research funding (to institution): Incyte, InnoCare, LOXO Oncology, Eli Lilly, MorphoSys, Novartis, Genentech, Genmab, AbbVie, BeiGene, Merck; Advisory board (compensation to institution): Eli Lilly, LOXO Oncology, TG Therapeutics, Incyte, InnoCare, Kite, Jansen, BeiGene, AstraZeneca, Genmab, AbbVie; Consultancy (compensation to institution): InnoCare, AbbVie; Honorarium (to institution): Kite.

Ethics approval and consent to participate

The study was approved by the Mayo Clinic Institutional Review Board. The study was conducted in compliance with the Declaration of Helsinki. Given the retrospective nature of the study, a waiver of consent was obtained.